Lumexa Imaging (LMRI) Q2 2026 Earnings Call Transcript

Lumexa Imaging reported Q2 2026 revenue of $264.2M (+5.1% YoY) and adjusted EBITDA of $56.4M (21.4% margin vs. 22.4% a year ago), alongside a swing to net income of $2.7M from a $7.2M net loss. The company narrowed full-year adjusted EBITDA guidance to $235M–$241M (midpoint $238M maintained) while reiterating adjusted EPS guidance of $0.71–$0.77, supported by record advanced modality mix (37.4% of volume, +111 bps YoY) and 23.2% YoY PET volume growth (+2 PET machines added in July). Free cash flow reached a record $23.1M (41% conversion of adjusted EBITDA), net leverage fell to 3.6x (from 5.7x), and management highlighted ~$4M annual interest savings starting in Q3 after a June 2026 term-loan repricing (SOFR +250 bps).

Analysis

LMRI is becoming less of a pure volume story and more of a capital-efficiency story: advanced imaging mix, PET rollout, and software-enabled capacity expansion let them grow revenue faster than headcount and CapEx. The key second-order effect is competitive displacement: a freestanding network with faster throughput and lower cost per scan can keep taking share from hospital outpatient departments even before any reimbursement change, because health systems care more about keeping high-acuity patients in-network than maximizing each individual scan.

The near-term read-through is modestly positive but not explosive. Margin was held back by non-operating and public-company costs, so the stock only works if investors underwrite a 2-step rerating: first on 2H seasonality/de novo ramp, then on lower leverage plus improving FCF conversion. The clean falsifier is a miss on 2H margin expansion or FCF conversion below the 25%-30% guide, which would imply the operating leverage is not as strong as management suggests.

Contrarian view: consensus may be overpricing the site-neutral proposal as a near-term catalyst. That policy is a multiyear accelerant, not a 1-2 quarter earnings driver, and the real upside probably comes from JV wins and capacity unlocks already in motion. The risk is that payor mix pressure or slower payer-rate realization offsets the mix shift, leaving the company with good growth but no multiple expansion. Watch for any slip in advanced mix below the mid/high-30s or a weaker-than-expected Q3 comp versus the 55% second-half earnings setup.

Key Decisions for Investors

• Long LMRI common on post-earnings weakness over the next 1-2 weeks; use a 3-6 month horizon for the H2 ramp/FCF rerating. Risk/reward is attractive if the market still values it like a steady imaging operator instead of a capacity compounder.
• If liquidity is sufficient, express the thesis with a 6-12 month LMRI call spread rather than naked calls: the catalyst path is medium-term, and the main downside is time decay if site-neutral timing slips.
• Pair trade idea: long LMRI / short hospital outpatient-heavy health systems (HCA or THC) for 6-18 months. Thesis is that site-neutral and lower-cost freestanding capacity gradually compress the hospital premium while LMRI captures volume share.
• Set a hard watch item on Q3: if adjusted EBITDA margin does not expand sequentially despite the seasonal setup and new PET/FastScan capacity, reduce exposure immediately.